Keith Katkin - Net Worth and Insider Trading

Keith Katkin Net Worth

The estimated net worth of Keith Katkin is at least $630,080 dollars as of 2024-11-06. Keith Katkin is the Director of Syndax Pharmaceuticals Inc and owns about 32,000 shares of Syndax Pharmaceuticals Inc (SNDX) stock worth over $630,080. Keith Katkin is also the PEO;CEO/Urovant Sciences, Inc. of Urovant Sciences Ltd and owns about 0 shares of Urovant Sciences Ltd (UROV) stock worth over $0. Details can be seen in Keith Katkin's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Keith Katkin has not made any transactions after 2022-10-06 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Keith Katkin

To

Keith Katkin Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Keith Katkin owns 6 companies in total, including Eledon Pharmaceuticals Inc (ELDN) , Rigel Pharmaceuticals Inc (RIGL) , and Urovant Sciences Ltd (UROV) among others .

Click here to see the complete history of Keith Katkin’s form 4 insider trades.

Insider Ownership Summary of Keith Katkin

Ticker Comapny Transaction Date Type of Owner
ELDN Eledon Pharmaceuticals Inc 2017-05-10 director
RIGL Rigel Pharmaceuticals Inc 2015-06-29 director
UROV Urovant Sciences Ltd 2020-02-19 director & PEO;CEO/Urovant Sciences & Inc.
LIMIT LIMIT 2022-10-06 director
LIMIT LIMIT 2015-08-03 director
LIMIT LIMIT 2022-04-01 director

Keith Katkin Latest Holdings Summary

Keith Katkin currently owns a total of 2 stocks. Among these stocks, Keith Katkin owns 32,000 shares of Syndax Pharmaceuticals Inc (SNDX) as of October 6, 2022, with a value of $630,080 and a weighting of 100%. Keith Katkin also owns 0 shares of Urovant Sciences Ltd (UROV) as of December 9, 2019, with a value of $0 and a weighting of 0%.

Latest Holdings of Keith Katkin

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
SNDX Syndax Pharmaceuticals Inc 2022-10-06 32,000 19.69 630,080
UROV Urovant Sciences Ltd 2019-12-09 0 16.24 0

Holding Weightings of Keith Katkin


Keith Katkin Form 4 Trading Tracker

According to the SEC Form 4 filings, Keith Katkin has made a total of 2 transactions in Syndax Pharmaceuticals Inc (SNDX) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Syndax Pharmaceuticals Inc is the sale of 29,899 shares on October 6, 2022, which brought Keith Katkin around $774,384.

According to the SEC Form 4 filings, Keith Katkin has made a total of 1 transactions in Urovant Sciences Ltd (UROV) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Urovant Sciences Ltd is the sale of 120,000 shares on December 9, 2019, which brought Keith Katkin around $2 Million.

Insider Trading History of Keith Katkin

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Keith Katkin Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Keith Katkin Ownership Network

Ownership Network List of Keith Katkin

No Data

Ownership Network Relation of Keith Katkin

Insider Network Chart

Keith Katkin Owned Company Details

What does Eledon Pharmaceuticals Inc do?

Who are the key executives at Eledon Pharmaceuticals Inc?

Keith Katkin is the director of Eledon Pharmaceuticals Inc. Other key executives at Eledon Pharmaceuticals Inc include other: See Explanation of Responses Biotechnology Value Fund L P , director & See Remarks Steven Perrin , and director & Chief Executive Officer David-alexandre C Gros .

Eledon Pharmaceuticals Inc (ELDN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Eledon Pharmaceuticals Inc (ELDN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eledon Pharmaceuticals Inc (ELDN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Eledon Pharmaceuticals Inc (ELDN)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Eledon Pharmaceuticals Inc Insider Transactions

No Available Data

Keith Katkin Mailing Address

Above is the net worth, insider trading, and ownership report for Keith Katkin. You might contact Keith Katkin via mailing address: C/o Urovant Sciences, Inc., 5281 California Avenue, Suite 100, Irvine Ca 92617.